November 04, 2021
Video
The staff member at the Mellen Center for Multiple Sclerosis discussed reasons why patients may stop treatment, as well as strategies for maintaining communication with the healthcare team in the event of discontinuation. [WATCH TIME: 5 minutes]
FDA Accepts New Drug Application for Intranasal Zavegepant to Treat Acute Migraine
Tackling Neurodegeneration in Multiple Sclerosis: Emily Harrington, MD, PhD
Periconceptional Folic Acid Supplementation Decreases Risk of Preterm Birth in Epilepsy
Changing the Future of Stroke Care: The 2021 ASA/AHA Prevention Guidelines